Amanda Hayward is a life science focused executive, with over 17 years experience in venture capital, company building, business development and corporate strategy. Prior to joining Velocity, she was at Baxalta/Shire, where she was a Partner at Baxalta Ventures, the strategic investment arm of Baxalta. In this capacity, she was a senior member of a dedicated team managing investments out of a fund targeted to therapeutic areas of interest to Baxalta, including immunology, oncology and hematology. In addition, Dr. Hayward was responsible for managing the Vitesse Biologics incubator on behalf of Baxalta Ventures, served as a Board Observer for Vitesse and as a member of the Board of Directors for Thunderbolt Pharma, a project focused company formed under the Vitesse Biologics umbrella.
Prior to Baxalta, Dr. Hayward was Senior Vice President at Scheer and Company Inc., where she spent 16 years working in venture origination and strategic corporate advisory services. During this time she played a significant role in founding multiple venture-backed companies from inception through sustainment, including Aegerion, Tengion, Optherion and Axerion. While at Scheer she also served as a strategic advisor to a variety of pharma and biotech companies, including in the orphan drug space, with a focus on business development and licensing.
Prior to Scheer, Dr. Hayward was at Yale, where she held the Life Sciences Research Foundation Bristol Myers Squibb Postdoctoral Fellowship. She currently serves as Executive Chairman for Hoba Therapeutics. She has a Bachelor of Science (Honors) in Genetics from University of Sheffield, and a Ph.D in Molecular Biology and Biochemistry from Texas Tech University Health Sciences Center.